Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXess™, its restorative vascular access conduit

Xeltis United States of America Netherlands United Kingdom Europe

aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, permanent, living vesselView original content:https://www.prnewswire.co.uk/news-releases/xeltis-receives-ide-approval-from-fda-for-initiation-of-us-pivotal-trial-for-axess-its-restorative-vascular-access-conduit-302171125.html